Ten-eleven translocation methylcytosine dioxygenase 2 (TET2) (TET2)

Ten-eleven translocation methylcytosine dioxygenase 2 (TET2) is a critical enzyme involved in the active DNA demethylation process by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) (UniProt: Q6N021). This epigenetic modification is essential for regulating gene expression patterns, particularly during hematopoietic stem cell differentiation and embryonic development (Tahiliani et al., Science, 2009). Mutations in TET2 are frequently observed in various hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), where they lead to a loss of 5hmC and subsequent genomic hypermethylation (Figueroa et al., Cancer Cell, 2010). In the context of cancer therapy, TET2 is considered a significant target because its activity can be modulated by cofactors like Vitamin C, which has been shown to restore enzyme function in TET2-deficient cells (Cimmino et al., Nature, 2017). Furthermore, TET2 is indirectly affected by mutations in IDH1 and IDH2, which produce the oncometabolite 2-hydroxyglutarate, a competitive inhibitor of TET2 activity (Xu et al., Cancer Cell, 2011). Therapeutic strategies currently explore the use of IDH inhibitors to relieve this inhibition or high-dose Vitamin C to enhance residual TET2 activity. Monitoring 5hmC levels in patient samples serves as a vital biomarker for assessing the functional status of the DNA demethylation pathway and the efficacy of these interventions.

Other names

TET2Ten-eleven translocation 25-methylcytosine dioxygenaseProbable methylcytosine dioxygenase TET2

Restoration of enzymatic activity through cofactor supplementation (e.g., Vitamin C) or indirect inhibition of competitive oncometabolites (e.g., 2-HG) via IDH1/2 inhibitors.